GSK was told about the results of studies of prospective two-component ART
ViiV Healthcare, a division of the British pharmaceutical company GlaxoSmithKline, spoke about the promising results of studies of innovative therapy against HIV of cabotegravir / rilpivirin, which will reduce the intake of necessary medications from a daily dose of three components to a monthly injection of two.
According to the Financial Times, the company expects that its development will increase the share of GSK in the ARVT market by $ 20 billion, and also draw manufacturers' attention to problems of toxicity and adherence by setting a new trend.
A representative of ViiV on Wednesday said that the Atlas study fulfilled its main task - to show the effectiveness of the two-component injectable "once-a-month" regimen (cabotegravir / rilpivirin) compared with the daily oral three-component ARV regimen.
These findings complement the June statement that another study of the oral two-part lamivudine / dolutegravir regimen, expected to be released by 2022, has proven to be safe and effective.
A two-component injection study involving 618 men and women living with HIV in 13 developed countries of the world was to determine whether HIV-positive adults with a suppressed viral load for at least six months in the traditional three-drug regimen would be able to maintain similar HIV suppression rates on a monthly regimen of cabotegravir / rilpivirin.
Analysis data showed that at 48 weeks of the study, two drugs administered once a month had similar efficacy with the traditional three-drug regimen.
According to the chief scientific and medical employee of ViiV Healthcare John Potay, the new approach is another step towards the potential reduction of the [toxic] burden on HIV-positive people.
"If this regime is approved, it will give people living with HIV a whole month between each dose of ARVT, changing treatment from 365 doses per year to 12."
Detailed results of the study will be presented at the forthcoming scientific meeting, the company said.
The results of the second study (Flair), designed to evaluate the duration of the injection of cabotegravir / rilpivirin in the group of patients who were not previously on ARVT, are expected at the end of this year.
GSK was informed that they intend to file documents with regulators for approval of the new regime.
